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Abstract: Several dicyclohexylidene tetraoxanes were prepared in order to gain a 
further insight into structure–activity relationship of this kind of antimalarials. The 
tetraoxanes 2–5, obtained as a cis/trans mixture, showed pronounced antimalarial 
activity against Plasmodium falciparum chloroquine susceptible D6, chloroquine 
resistant W2 and multidrug-resistant TM91C235 (Thailand) strains. They have 
better than or similar activity to the corresponding desmethyl dicyclohexylidene 
derivatives. Two chimeric endoperoxides with superior antimalarial activity to the 
natural product ascaridole were also synthesized. 
Keywords: mixed tetraoxanes, endoperoxides, malaria, P. falciparum. 
INTRODUCTION 
Malaria affects more than 500 million people per annum, causing more than 
one million deaths, mostly in Africa.1 Infants, young children and pregnant wo-
men are particularly at risk; in fact, it has been estimated that a child dies of 
malaria every 30 seconds. Furthermore, the disease has as an immeasurable nega-
tive impact, both personally and socioeconomically, on families and communities 
in endemic areas. Although malaria is treatable, increased resistance of the pro-
tozoan parasite Plasmodium falciparum to standard and affordable anti-malarial 
drugs, such as chloroquine (CQ), complicates the treatment of infected indivi-
duals. Peroxide antimalarials of the 1,2,4-trioxacyclohexane class (artemisinin 
and its derivatives)2 and drugs of the trioxolane class3 offer some new possibili-
ties for treating malaria. 
Compounds of another peroxide class, the 1,2,4,5-tetraoxacyclohexanes (te-
traoxanes), although less investigated, also have been shown to have potent anti-
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malarial activity.4 Subsequently, the syntheses of mixed tetraoxanes5,6 enabled 
the controlled preparation of a new generation of this promising class of antima-
larials.* In addition to the steroidal tetraoxanes, a significant number of dicyclo-
hexylidene tetraoxanes have been synthesized and their anti-malarial activity 
evaluated both in vitro and in vivo.8,9 
Monoterpene ascaridole (Scheme 1), a natural bicyclic [2.2.2] endoperoxide 
with moderate antimalarial properties, was used as a model for the synthesis of a 
series of diaryl substituted ascaridole-type endoperoxides, which showed higher 
activity as compared to ascaridole or dihydroascaridole.10 More recently, the 
syntheses of less volatile ascaridole and dihydroascaridole derivatives have been 
accomplished starting from perillyl and nopol derivatives.11 
 
Scheme 1. 
Here are reported the synthesis and results of anti-malarial screening of two 
types of anti-malarial peroxides: mixed tetraoxanes, the derivatives of 12-methyl-
-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylic acid, and endopero-
xides, monoterpene ascaridole derivatives, bound to another anti-malarial phar-
macophore, 4-amino-7-chloroquinoline. In addition, the results of in vivo scre-
ening of some mixed steroidal tetraoxanes are also discussed. 
RESULTS AND DISCUSSION 
Chemistry 
The class of dicyclohexylidene tetraoxanes (2–5) was designed with varying 
substituents at the C(4") position in order to obtain further insight into the struc-
ture–activity relationship related to spiro-substituents in 1,2,4,5-tetraoxacyclo-
hexane at C(3) and C(6). Gem-dihydroperoxide 1 was prepared from 4-methylcy-
clohexanone using 30 % hydrogen peroxide and HCl as a catalyst.5a Compound 1 
was isolated in 47–85 % yield and was pure enough (Scheme 2) to be directly 
used in the next step.** This gem-dihydroperoxide was coupled to 4-oxocyclohe-
                                                                                                                    
* The structure of the previously evaluated dicyclohexylidene tetraoxanes was limited by a syn-
thetic constraint: only bis compounds could be obtained directly from the corresponding ketones.7 
** For alternative excellent syntheses of gem-dihydroperoxides, see reference 12. 
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xanecarboxylate according to a previously developed procedure5a to yield the pa-
rent mixed tetraoxane, achiral methyl 12-methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]he-
xadecane-3-carboxylate (2; 10–35 %). Further transformations using the ester → 
→ acid → amide sequence (Scheme 2) afforded the desired amides 4 and 5 in 59 % 
and 49 % yield, respectively. 
 
Scheme 2. 
Ascaridole derivatives 6 and 7 synthesized earlier11 were hydrolysed with 
LiOH into the corresponding acids and further coupled to N-(7-chloroquinolin-4-
-yl)ethane-1,2-diamine to afford the final aminoquinoline products 8 and 9, res-
pectively (Scheme 1). 
Antimalarial activity 
The synthesized peroxides were screened in vitro against three Plasmodium 
falciparum strains: D6 (chloroquine-susceptible), W2 (chloroquine-resistant, sus-
1184 OPSENICA et al. 
ceptible to mefloquine), and TM91C235 (Thailand), a multidrug-resistant strain, 
following the protocol given in the literature.5a All the synthesized tetraoxanes 
exhibited interesting antimalarial activity. In accordance with previous fin-
dings,5a the acid 3 was less active (in this particular case – practically inactive) 
than the methyl ester 2 and the corresponding amides 4 and 5 against all parasite 
strains. One of the current hypotheses regarding the mechanism of antimalarial 
action of peroxides is that they act in the food vacuole (FV) of P. falciparum, 
which has a pH around 5.5. As such, amide 5 was designed to have an N,N-di-
methylamino group, expecting that protonation of the basic nitrogen would en-
hance the flux of the compound through the FV membrane, thereby increasing its 
concentration at the desired site of action. However, the in vitro antimalarial acti-
vity data for tetraoxane 5 (Table I) does not support this hypothesis, since amide 
4 (which possesses only an acidic hydrogen at the nitrogen) and ester 2 exhibit 
very similar activity (both IC50 and IC90) against all the tested parasites. In ad-
dition, the activities of the dicyclohexylidene tetraoxanes presented in this paper 
are better or equivalent to similar desmethyl compounds.6d,9 
TABLE I. In vitro antimalarial activities of tetraoxanes 2–9 against P. falciparum D6,a W2,b and 
TM91C235c strains 
IC50 / nM IC90 / nM Compd. 
D6 W2 TM91C235 D6 W2 TM91C235 
2 12.9 6.1 16.0 32.0 20.5 57.5 
3 206.6 131.4 300.4 506.9 487.1 1110.1 
4 13.6 8.4 18.8 22.1 22.5 41.1 
5 14.9 6.1 22.6 23.9 15.8 45.5 
6 109.0 42.7 98.2 196.5 68.5 338.9 
7 41.4 20.2 47.4 62.5 ND 112.7 
8 101.1 58.6 99.7 156.4 140.8 221.4 
9 38.3 30.4 60.6 111.6 89.7 200.7 
Chloroquine 8.6 354.3 113.7 10.7 653.0 166.0 
Mefloquine 17.1 4.7 49.5 36.1 15.5 121.0 
Artemisinind 9.0 6.7 13.0 12.8 11.5 17.4 
aP. falciparum African D6 clone; bP. falciparum Indochina W2 clone; cP. falciparum multidrug resistant 
TM91C23 strain (Thailand); daverage of greater than eight replicates 
The antimalarial activity of compounds 6–9 appears to be strongly dependent 
on the degree of saturation: the saturated bicyclic endoperoxides (7,9) are more 
potent antimalarials relative to their unsaturated counterparts (Table I), and both 
unsaturated (6,8) and saturated (7,9) endoperoxides are 5–12 times more active 
than ascaridole and dihydroascaridole themselves. These results indicate that pe-
roxide–aminoquinoline chimeras, in addition to the trioxaquines,13 might repre-
sent a promising addition to the existing antimalarial arsenal. 
Finally, the results of an in vivo study on the epimeric mixed steroidal tetra-
oxanes 10 and 11 (Table II) are presented.5a The in vitro activity of the com-
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pounds differs 20- to 30-fold, with the (4"R)-epimer 10 being more active; this 
structure-activity relationship qualitatively holds for other epimeric pairs at the 
same carbon.5 Docking calculations of 10 and 11 with heme14 are consistent with 
the observation that the proximity of the heme iron to the oxygen atom of the 
tetraoxane moiety favours potent in vitro activity of both compounds. The more 
potent analogues have much lower energy minimized docked structures. In addi-
tion, preliminary metabolic stability assays and metabolite identification were 
performed using human and mouse liver microsomes to aid the estimation of the 
first-pass metabolism of the drug candidates in relevant species (Table II).5c It is 
important to note that no scission of peroxide bond was observed (the tetraoxane 
moiety is stable in this assay); only monohydroxylations occurred. In this as-
say,5c stable compounds were defined as having half-lives > 60 min. Both com-
pounds have similar metabolic half-lives (t1/2(mouse) ≅ 30 min). Hence, it would 
be logical that the observed difference in in vitro activity would also be seen in 
the in vivo efficacy test in mice. However, the collective in vivo results presented 
in Table II are not consistent with results from the in vitro screening and with the 
docking calculations: epimers 10 and 11 exert similar in vivo activity in mice, 
regardless of whether they were administered orally or subcutaneously (Table II). 
Furthermore, at 600 mg/kg total dose p.o. and 480 mg/kg total dose s.c. of tetra-
oxane 10, 4/5 and 5/5 mice cured were observed and the respective survival times 
were 28 and 31 days. At a total dose 150 mg/kg p.o. and 120 mg/kg s.c., very si-
milar survival times were observed. 
Analogous results were also seen for epimer 11. In addition, at comparable 
total doses of 150 mg/kg p.o. and 120 mg/kg s.c., compounds 10 and 11 both cured 
more animals orally than subcutaneously. This apparent higher bioavailability by 
the oral route may have resulted from a lack of absorption due to s.c. depot for-
mation: a subcutaneous sterile pocket of oil and unabsorbed test compound was 
commonly found in each animal. Alternatively, one of the hydroxylated metabo-
lites formed after oral administration may be more active than the administered 
parent drug. For both compounds, 10 and 11, no toxic effects were observed at 
any tested concentration or applied protocol. 
To conclude, several dicyclohexylidene tetraoxanes were prepared and tested 
in order to gain additional insight into the structure-activity relationship of this 
structural class of antimalarials. The tetraoxanes 2–5 obtained as cis/trans mix-
tures exerted better, or similar activity, than the corresponding desmethyl dicy-
clohexylidene derivatives.6d,9 The initial work on ascaridole-related compounds11 
enabled the synthesis of two chimeric endoperoxides with superior antimalarial 
activity to the natural product, ascaridole. The present results indicate that further 
efforts should be put into research of peroxide–aminoquinoline chimeras as po-
tential antimalarial drug leads. Finally, the results of in vivo tests of two epimeric 
tetraoxanes with a steroidal carrier indicate that subcutaneous testing using an oil 
vehicle for these compounds may be unsuitable. 
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EXPERIMENTAL 
General remarks 
For details, please see references 5a, 5b, 5c. 
ESI MS spectra of the synthesized compounds were recorded on an Agilent Technologies 
6210 Time-of-Flight LC/MS instrument in the positive ion mode using CH3CN/H2O = 1/1 with 
0.2 % HCOOH as the carrying solvent solution. The samples were dissolved in pure acetonitrile 
(HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 
350 °C; drying gas 12 l min-1; nebuliser pressure 45 psig; fragmentator voltage 70 V. 
1,1-Dihydroperoxy-4-methylcyclohexane (1) 
4-Methylcyclohexanone (1.1 ml, 8.9 mmol) was dissolved at r.t. in a CH2Cl2/CH3CN mixture 
(20 ml, 1:3 v/v), followed by addition of 30 % H2O2 (10.4 ml, 0.1 mol) and a few drops of conc. 
HCl. The reaction mixture was stirred for 2 h at r.t. and then quenched with saturated NaHCO3 and 
CH2Cl2. The organic layer was separated, the water layer was additionally extracted with EtOAc 
(3×50 ml), and the combined organic layers were dried over anhydrous MgSO4 and evaporated to 
dryness. The crude product (680 mg, 47 %) was used in the following step without further 
purification. IR (film, cm-1): 3420s, 2935s, 2865s, 1712m, 1637w, 1554m, 1378m, 1357m, 1265m, 
1200w, 1158m, 1104m, 1050m, 1017m, 980m, 910m, 861m cm-1. IR (CCl4, cm-1): 3431m, 2957s, 
2930s, 2865m, 1712w, 1551s, 1454m, 1384m, 1357m, 1255s, 1222s, 1162w, 1103m, 1071m, 1012s, 
980s. 1H-NMR (200 MHz, CDCl3, δ, ppm): 9.40−9.00 (m, 2×HOO−C(1)), 2.30−2.00 (m), 1.70−1.30 
(m), 1.30−1.10 (m), 0.93 (d, H3C−C(4), J = 6.2 Hz). 13C-NMR (50 MHz, CDCl3, δ, ppm): 110.73, 
40.83, 31.59, 30.58, 29.03, 21.38. 
Methyl 12-methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylate (2) 
To a cooled solution (ice bath) of dihydroperoxide 1 (1.2 g, 7.4 mmol) in CH2Cl2 (20 ml), 
methyl 4-oxocyclohexanecarboxylate was added and after stirring for 30 min at the same tempera-
ture, 1.66 ml of an ice-bath cooled H2SO4/CH3CN mixture (1:10, v/v) was added dropwise. After 
an additional 50 min stirring, the reaction mixture was worked-up in the usual manner and purified 
by SiO2 column chromatography (Lobar B, LichroPrep Si 60, eluent: heptane/EtOAc = 95/5) affor-
ding 222 mg (10 %) 2.* 2: Colourless foam, softens at 57−59 °C. IR (KBr, cm-1): 3449w, 2958s, 
2938m, 2860m, 1736s, 1442m, 1368m, 1329m, 1265m, 1201s, 1182m, 1133m, 1074s, 976m, 932m, 
897m, 828w. 1H-NMR (200 MHz, CDCl3, δ, ppm): 3.68 (s, CH3CO2−C(1)), 2.98 (bs, 2 H), 2.51−2.32 
(m, 1H), 2.02−1.14 (m, 15 H), 0.93 (d, CH3−C(12), J = 6.6 Hz). 13C-NMR (50 MHz, CDCl3, δ, 
ppm): 175.01, 108.33, 107.22, 51.64, 41.51, 41.30, 31.61, 31.55, 31.26, 30.21, 28.86, 28.09, 24.53, 
23.76, 21.30. (+)ESI–MS (m/z (%)): 304.4 (100), 284.4 (58), 244.3 (25), 164.2 (21), 159.2 (51). 
Anal. calcd. for C15H24O6⋅1/4 H2O: C 59.10, H 8.10; Found: C 59.52, H 8.72. 
12-Methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylic acid (3) 
Methyl ester 2 (400 mg, 1.3 mmol) was hydrolyzed at 80 °C with NaOH (72.8 mg, 1.82 
mmol) in an i-PrOH/H2O mixture (12 ml, 3:1 v/v). After 15 min, the reaction mixture was cooled 
and diluted with 20 ml H2O and 50 ml CH2Cl2. The water layer was acidified to pH 2 with dilute 
HCl, and layers were separated. The water layer was further extracted with CH2Cl2 (3×20 ml); the 
combined organic layers were washed with water and brine, dried over anh. MgSO4, and evapora-
ted to dryness. Triturating with Et2O afforded 305 mg (80 %) of product. m.p. 134−137 °C. IR 
(KBr, cm-1): 3449m, 2948s, 2870m, 1707s, 1447m, 1324w, 1270m, 1226m, 1069m, 976m, 936m. 
1H-NMR (200 MHz, CDCl3, δ, ppm): 2.99 (bs, 2H), 2.60−2.31 (m, 1H), 2.03−1.12 (m, 15 H), 0.93 
(d, CH3−C(12), J = 6.2 Hz). 13C-NMR (50 MHz, CDCl3, δ, ppm): 180.73, 108.44, 107.19, 41.30, 
41.08, 31.65, 31.61, 30.24, 24.29, 21.38. (–)ESI–MS (m/z (%)): 285.0 ([M−H]–, 89), 104.9 (100). 
Anal. calcd. for C14H22O6⋅1/4 H2O: C 57.52, H 7.82; Found: C 57.99, H 8.39. 
                                                                                                                    
* The yields varied within 10–35 %. 
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General procedure for the preparation of amides 
A solution of acid 3 (103 mg, 0.36 mmol) in dry CH2Cl2 (20 ml), with added Et3N (51 µl, 
0.36 mmol) and ClCO2Et (35 µl, 0.36 mmol) was stirred for 90 min at 0 °C. A given amount of 
amine was added and after 30 min stirring, the reaction mixture was warmed to r.t. After 90 min it 
was diluted with H2O, the layers were separated and the organic layer was washed with brine, dried 
over anh. MgSO4 and evaporated to dryness. 
12-Methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxamide (4) 
Acid 3 was transformed into amide 4 (75 mg, 74 %), which upon triturating with Et2O af-
forded a sample having m.p. 161−165 °C. IR (KBr, cm-1): 3402s, 3210m, 2949m, 2860w, 1653s, 
1441m, 1372w, 1234m, 1077m, 978w, 940w, 904w. 1H-NMR (200 MHz, CD3OD, δ, ppm): 3.40−3.10 
(bs, 2H), 2.60−2.40 (m, 1 H), 2.10−1.20 (m, 15 H), 1.12 (d, CH3−C(12), J = 6.3 Hz). 13C-NMR (50 
MHz, CD3OD, δ, ppm): 180.79, 109.27, 108.36, 44.28, 32.92, 32.30, 31.61, 29.99, 29.43, 26.59, 
25.69, 21.83, 9.29, 7.58. (+)ESI–MS (m/z (%)): 327.3 (18), 286.2 ([M+H]+, 15), 152.2 (28), 150.2 
(90), 142.2 (25), 102.3 (32), 100.3 (55), 83.3 (100). Anal. calcd. for C14H23NO5⋅2/3 H2O: C 56.55, 
H 8.25, N 4.71; Found: C 56.24, H 8.59, N 5.03. 
N-(2-dimethylamino-ethyl)-12-methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxamide (5) 
Acid 3 (103 mg, 0.36 mmol) was transformed into amide 5 (79 mg, 61 %) using 10 equiva-
lents of (CH3)2NCH2CH2NH2 in dry CH2Cl2 (25 ml). Upon triturating with Et2O, a colourless foam 
was obtained, softness at 140−145 °C. IR (KBr, cm-1): 3443m, 3317s, 2946s, 2873m, 2824m, 
2775m, 1649s, 1556s, 1449m, 1371w, 1264w, 1220m, 1069m, 976w, 927m. 1H-NMR (200 MHz, 
CDCl3, δ, ppm): 6.20 (bs, HN−CO), 3.40−3.30 (m, (CH3)2NCH2CH2NH−CO)), 3.10 (bs, H–C(1)), 
2.45−2.35 (m, (CH3)2NCH2CH2NH−CO)), 2.35−2.10 (m, (CH3)2NCH2CH2NH−CO)), 1.90−1.10 
(m, 15H), 0.93 (d, CH3−C(12), J = 6.2 Hz). 13C-NMR (50 MHz, CDCl3, δ, ppm): 174.50, 108.39, 
107.31, 57.65, 45.01, 43.99, 43.77, 36.45, 31.65, 31.57, 28.42, 24.76, 21.32. (+)ESI–MS (m/z (%)): 
357.3 ([M+H]+, 100). Anal. calc. for C18H32N2O5 1/2 H2O: C 59.16, H 9.10, N 7.67; Found: C 
59.39, H 9.61, N 7.75. 
(E)-N-{2-[(7-chloro-4-quinolinyl)amino]ethyl}-3-(4-isopropyl-2,3-dioxabicyclo[2.2.2]oct-5-en-1- 
-yl)-2-propenamide (8) 
Employing the above procedure, compound 6 was hydrolysed and the intermediate acid11 was 
transformed into amide 8 (31 mg, 91 %), which was then triturated with Et2O. Oil. 8: 1H-NMR 
(200 MHz, CDCl3, δ, ppm): 8.42 (m, H−C(2')), 7.90 (m, H−C(5')), 7.83 (m, H−C(8')), 7.36 (m, 
H−C(6')), 7.03 (d, 1H, J = 15.6 Hz), 6.95 (bs, NH−Ar), 6.62 (bs, NH−CO), 6.58 (d, 1H, J = 8.7 
Hz), 6.49 (d, 1H, J = 8.7 Hz), 6.26 (m, H−C(3')), 6.14 (d, 1H, J = 15.6 Hz), 3.80−3.70 (m, 
CONHCH2CH2NHAr), 3.48−3.36 (m, CONHCH2CH2NHAr), 2.20−1.95 (m, 4H), 1.50−1.70 (m, 1H), 
1.02 (m, 6H). 13C-NMR (50 MHz, CDCl3, δ, ppm): 167.53, 150.90, 150.54, 147.94, 143.44, 141.80, 
135.30, 133.77, 127.36, 125.59, 123.83, 122.30, 117.00, 98.08, 80.79, 75.60, 45.43, 38.93, 32.06, 
28.91, 24.54, 17.53, 17.08. (+)ESI–HRMS (m/z (%)): 428.1735 ([M+H]+, 100); calculated 428.1736. 
N-{2-[(7-chloro-4-quinolinyl)amino]ethyl}-3-(4-isopropyl-2,3-dioxabicyclo[2.2.2]oct-1-yl)propanamide (9) 
Employing the above procedure, compound 7 was hydrolysed and the intermediate acid11 was 
transformed into amide 9 (32 mg, 85 %), which was then triturated with Et2O. Oil. 9: 1H-NMR 
(200 MHz, CDCl3, δ, ppm): 8.45 (m, H−C(2')), 7.88 (m, H−C(5')), 7.78 (m, H−C(8')), 7.33 (m, 
H−C(6')), 6.65 (bs, NH−Ar), 6.45 (bs, NH−CO), 6.24 (m, H−C(3')), 3.69−3.65 (m, 
CONHCH2CH2NHAr), 3.39−3.37 (m, CONHCH2CH2NHAr), 2.31−2.28 (t, 2H, J = 9.0 Hz), 1.94−1.88 
(m, 4H), 1.84−1.78 (m, 2H), 1.67−1.57 (m, 5H), 0.86 (d, 6H, J = 7.0 Hz). 13C-NMR (50 MHz, 
CDCl3, δ, ppm): 175.56, 151.80, 150.15, 148.93, 134.91, 128.24, 125.43, 122.07, 117.26, 98.17, 
79.70, 76.08, 45.61, 38.79, 34.15, 33.23, 30.25, 28.87, 25.68, 16.85. (+)ESI-HRMS (m/z (%)): 
432.2050 ([M+H]+, 100); calculated 432.2048. 
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In vitro antimalarial activity 
The in vitro antimalarial drug susceptibility screen was a modification of the procedures first 
published by Desjardins et al.,15 with modifications developed by Milhous et al.,16 with the details 
given in ref. 4c. 
In vivo antimalarial activity 
The P. berghei mouse efficacy tests were conducted using a modified version of the Thomp-
son test. On day 0, each mouse was inoculated intraperitoneally with 0.1 ml, 1.0×106 P. berghei  
P-line infected red blood cells from donor mice. The test drugs at 10, 20, and 80 mg/kg were sus-
pended or dissolved in sesame oil and administered s.c. beginning on day 3 post-infection. Drug 
administrations were performed twice per day at 12 hours intervals for 3 days. The dose levels are 
given in Table II. Cure was defined as survival until day 31 post-treatment. Untreated control mice 
typically died on day 7−9 post-infection. 
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Reed Army Institute of Research, Washington, DC 20307-5100, USA, 3Department of Chemistry, University of 
Crete, Voutes, 71003 Iraklion, Greece i 4Hemijski fakultet Univerziteta u Beogradu, p. pr. 158, Beograd 
У овом раду приказана је синтеза неколико дицикилохексилиденских тетраоксана у 
циљу сагледавања односа структура–активност ове врсте антималарика. Једињења 2–5 доби-
јена као (cis,trans)-смесе показала су изражену антималаријску активност према D6, W2 и 
TM91C235 (Thailand) сојевима P. falciparum. Она имају бољу или сличну активност од одго-
варајућих десметил циклохексилиденских деривата. Синтетисана су и два ендопероксида хи-
мерне структуре знатно израженије активности од природног производа аскаридола. 
(Примљено 6. септембра 2007) 
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